Treatment of lung cancer

Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference

Retrieved on: 
Tuesday, April 12, 2022

Pancreatic cancer remains a high unmet medical need with limited treatment options. According to the American Cancer Society, about 62,210 will be diagnosed with pancreatic cancer in the United States. in 2022, and more than 49,830 patients will die from the disease -- the highest mortality rate of all major cancers. For advanced disease, chemotherapy (sometimes along with a targeted drug therapy) may lengthen survival.1

Key Points: 
  • In three of these models, significant changes in tumor growth were observed in those that received QN-302, together with good tolerance and bioavailability at therapeutic doses.
  • This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release.
  • The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer

Retrieved on: 
Thursday, April 7, 2022

SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG (serplulimab) for the treatment of small cell lung cancer (SCLC).

Key Points: 
  • SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG (serplulimab) for the treatment of small cell lung cancer (SCLC).
  • According to GLOBOCAN 2020, lung cancer (LC) is the second most common cancer around the world.
  • The NDA of the treatment for squamous non-small cell lung cancer (sqNSCLC) has been accepted by theNMPA andis expected to be approved in 2022.
  • Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer.

ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

Retrieved on: 
Friday, April 1, 2022

All data for QUILT-3.032, which is studying VesAnktiva plus BCG in subjects with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), have been locked and analyzed.

Key Points: 
  • All data for QUILT-3.032, which is studying VesAnktiva plus BCG in subjects with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), have been locked and analyzed.
  • The BLA has been compiled and, following final quality review, is expected to be submitted to the U.S. Food and Drug Administration (FDA) this month.
  • The FDA granted Fast Track Designation to the pivotal trial based on Phase I data.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

Retrieved on: 
Wednesday, March 30, 2022

TD2 is a precision oncology drug development organization integrating preclinical, clinical, and regulatory expertise and providing expert drug development services, including the design and execution of oncology clinical trials.

Key Points: 
  • TD2 is a precision oncology drug development organization integrating preclinical, clinical, and regulatory expertise and providing expert drug development services, including the design and execution of oncology clinical trials.
  • We are eager to begin our collaboration with Qualigen and to develop a research program for QN-302 that results in a suitable dataset for regulatory clearance.
  • About Translational Drug Development (TD2), Inc.
    TD2 is a leader in precision oncology, providing innovative services for improved drug development.
  • Using a dedicated, expert team with broad experience and understanding in cancer medicine, TD2 is uniquely positioned to support accelerated development of novel therapeutics.

Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference

Retrieved on: 
Tuesday, March 22, 2022

CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today provides data from published abstracts from the American Association of Cancer Research (AACR) demonstrating positive in vivo data on the Company’s lead compound QN-302 (previously known and referenced in the abstracts as SOP1812).

Key Points: 
  • These data represent an important step forward in our lead development program, QN-302, particularly with regard to pancreatic cancer and prostate cancer, commented Michael Poirier, Qualigens CEO.
  • The presentation of these data at AACR shows promising information regarding the key properties of this therapeutic target.
  • The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer (lead author Dr. Stephen Neidle, to be posted April 13).
  • These abstract reports that QN-302 showed significant anti-tumor activity in three patient-derived xenograft (PDX) models for pancreatic ductal adenocarcinoma (PDAC).

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

Retrieved on: 
Tuesday, March 8, 2022

Advancing the sixth FixVac product candidate based on uridine mRNA into clinical development underlines the versatility and potential of this platform.

Key Points: 
  • Advancing the sixth FixVac product candidate based on uridine mRNA into clinical development underlines the versatility and potential of this platform.
  • We look forward to further building on our successful collaboration with Regeneron to accelerate the clinical development of BNT116 in our growing mRNA oncology pipeline.
  • The companies plan to develop the collaboration beginning with Phase 1/2 clinical trials in the first-line treatment setting in advanced NSCLC.
  • The agreement follows the companys existing collaboration evaluating the combination of BioNTechs FixVac candidate BNT111 with Libtayo in advanced melanoma.

Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio’s Scaled m-ceNK Clinical Program

Retrieved on: 
Wednesday, March 2, 2022

The results were recently published in a peer-reviewed article (Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia) in Science Translational Medicine.

Key Points: 
  • The results were recently published in a peer-reviewed article (Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia) in Science Translational Medicine.
  • NK cells are innate immune cells that are under investigation as a cell therapy for multiple types of cancer.
  • Together, these findings support the use of memory NK cells as a component of HCT for leukemia.
  • The study also showed that stimulated memory NK cells are effective with only a single infusion when given along with Anktiva support.

Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Retrieved on: 
Monday, February 14, 2022

In contrast to approved therapies, targeting Class I BRAF alterations, KIN-2787 was most active in Class II and Class III BRAF-altered NSCLC cells.

Key Points: 
  • In contrast to approved therapies, targeting Class I BRAF alterations, KIN-2787 was most active in Class II and Class III BRAF-altered NSCLC cells.
  • In vivo, KIN-2787 efficacy was evaluated using a BRAF-alteration driven human NSCLC cell line and patient-derived xenograft models.
  • The ongoing KN-8701 trial ( NCT# 04913285 ) of KIN-2787 is actively enrolling patients across multiple centers in the United States.
  • Details of the meeting presentation are as follows:
    Additional information on the virtual IASLC 2022 Targeted Therapies of Lung Cancer meeting is available at: https://ttlc2022.iaslc.org .

Teclison Completes $5.9 Million Capital Raise

Retrieved on: 
Monday, February 14, 2022

PRINCETON, N.J., and TAIPEI, Taiwan, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, announced the completion of a $5.9 million in gross proceeds capital raise.

Key Points: 
  • PRINCETON, N.J., and TAIPEI, Taiwan, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, announced the completion of a $5.9 million in gross proceeds capital raise.
  • Investment, the family office of Taiwans Tsai family, with participation from new and existing U.S. and Taiwan investors, including Nestor Capital.
  • Teclison has a Clinical Trial Collaboration and Supply Agreement with Merck & Co. (known as MSD outside of the U.S. and Canada) to study TEC-001 in combination with their immunotherapy drug portfolio.
  • Teclison is a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity.

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

Retrieved on: 
Monday, February 14, 2022

The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ (NMIBC CIS) bladder cancer (Cohort A) and with papillary disease (Cohort B).

Key Points: 
  • The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ (NMIBC CIS) bladder cancer (Cohort A) and with papillary disease (Cohort B).
  • In the papillary disease arm of the study (Cohort B), 57% of patients are disease free at 12 months and 53% at 18 months.
  • This study suggests that BCG induces trained immunity as the prime, while N-803 serves as a vital boost for innate immune memory.
  • The latest data from this trial exceeds AUA-FDA workshop benchmarks for both the magnitude of complete remission and the duration of complete response for new therapies for BCG-unresponsive bladder cancer.